Staphylococcus vaccine

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Revision as of 04:39, May 11, 2020 by JaimeS (talk | contribs) (Protected "Staphylococcus vaccine" ([Edit=Allow only established/autoconfirmed users (semi-protection)] (indefinite)))

Staphylococcus vaccine (Staphypan) has been proposed as an immunomodulatory therapy in the treatment of Chronic Fatigue Syndrome. It was first used in Sweden with patients who became ill after a 1957 outbreak of Asian flu.[1]

A Swedish study found significant improvement in Fibromyalgia and Chronic Fatigue Syndrome patients with a mean reduction in CPRS-15 scores of 50%.[2][3]

A second study found significantly increased capacity of serum to neutralise alpha-toxin and a significant increase in serum IgG to alpha-toxin and lipase in patients receiving Staphypan.[4]

Staphypan is no longer being commercially manufactured.[1] Another staphylococcal toxoid vaccine made by the Russian pharmaceutical company Medgamal is being used by some ME/CFS patients (see here), but it does not contain the same antigens as Staphypan. Its efficacy is unclear, but is thought to work to a degree, though less effective than Staphypan.

Staphylococcal vaccine favors Th1 dominance.[citation needed]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 YouTube - Interview with Professor Carl-Gerhard Gottfries, Part 1: Background and Vaccine
  2. IACFS/ME - Immunotherapy of Fibromyalgia and Chronic Fatigue Syndrome by a Staphylococcus Toxoid Vaccine
  3. Zachrisson, Olof; Regland, Björn; Jahreskog, Marianne; Jonsson, Michael; Kron, Margareta; Gottfries, Carl-Gerhard (2002), "Treatment with staphylococcus toxoid in fibromyalgia/chronic fatigue syndrome--a randomised controlled trial", European Journal of Pain (London, England), 6 (6): 455–466, ISSN 1090-3801, PMID 12413434
  4. Zachrisson, O.; Colque-Navarro, P.; Gottfries, C. G.; Regland, B.; Möllby, R. (February 2004), "Immune modulation with a staphylococcal preparation in fibromyalgia/chronic fatigue syndrome: relation between antibody levels and clinical improvement", European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology, 23 (2): 98–105, doi:10.1007/s10096-003-1062-8, ISSN 0934-9723, PMID 14735403